Please assess the completion status of the following clinical trial:

Trial Title: RESPOND Restoring Equilibrium and Wound Stimulation to Promote Healing Of Non-healing DFUs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject of any race and at least 18 to 90 years old~* Lower extremity full thickness diabetic foot ulcer of 30-364 days duration~* Subject's wound must be between 2cm² and 20cm² at screening~* Subject's wound must be at or below the malleolus~* Documented ABI is between 0.8 and 1.2 on the study limb or transcutaneous partial pressure oxygen (TcpO2) \> 40 mmHG; or a toe pressure \> 40 mmHG; or a Doppler waveform consistent with adequate flow in the foot (biphasic or triphasic waveforms) within 30 days of screening.~* Subject or subject's legally authorized representative understands the nature of the procedure(s) and provides written informed consent prior to study enrollment~* Subject is willing and able to comply with all specified care and visit requirements~* Subject and/or caregiver must be willing and able to learn and perform the duties of dressing changes, and demonstrate the ability to do so.~Exclusion Criteria:~* Index ulcer wound has exposed tendons, ligaments, muscle, or bone~* Index ulcer wound presents with clinical signs of acute infection, suspected or known~* Subjects with evidence of osteomyelitis or cellulitis or gangrene in the study limb~* Subjects with active Charcot's foot on the study limb~* Subjects with amputation above a Trans Metatarsal Amputation (TMA) in the affected limb~* Subjects with active malignancy on the study limb except non-melanoma skin cancer~* Subjects with planned vascular surgery, angioplasty or thrombolysis procedures within the study period~* Subjects within 6 weeks post-operatively of a vascular procedure.~* Subject has had prior skin replacement, negative pressure therapy, or ultrasound therapy applied to the index wound in the 14 days prior to screening~* Subjects who have received oral, or IV antibiotic/antimicrobial agents or medications have been used within 2 days (48 hours) of baseline.~* Subjects who have received topical antibiotic/antimicrobial agents or dressings at the index wound site within 2 days (48 hours) of baseline.~* Subjects currently taking steroids of \>10mg dosage~* Subject has received growth factor therapy (e.g., autologous platelet-rich plasma gel, becaplermin, bilayered cell therapy, dermal substitute, extracellular matrix) within 14 days of screening date.~* Subject is currently receiving or has received radiation or chemotherapy within 3 months of randomization.~* Subject has one or more medical condition(s), uncontrolled diabetes (HbA1c \> 12), renal, hepatic, hematologic, neurologic, or immune disease that in the opinion of the investigator would make the subject an inappropriate study candidate~* Subject allergic to a broad spectrum of primary \& secondary dressing materials, including occlusive dressings and the adhesives on such dressings.~* Female subjects that are pregnant or refuse to utilize adequate contraceptive methods and are of childbearing age during the trial.~* Subject is known to be suffering from a disorder or other situation that the subject or investigator feels would interfere with compliance or other study requirements~* Subject is currently enrolled or has been enrolled in the last 30 days in another investigational device or drug trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- SOC - Standard of Care (Type: ACTIVE_COMPARATOR): Wound cleansing and debridement as needed, moist wound healing dressing, and off-loading
- SOC + MIST Therapy (Type: ACTIVE_COMPARATOR): Wound cleansing and debridement as needed, moist wound healing dressing, off-loading, and MIST treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).